Opioids and motor complications in Parkinson's disease

Trends in Pharmacological Sciences

Volumn 27, Issue 10, 2006, Pages 512-517

  Samadi, Pershia ^a   Bédard, Paul J ^a   Rouillard, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; ALPHA 2A ADRENERGIC RECEPTOR; ANTIPARKINSON AGENT; CYCLIC AMP; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; KAPPA OPIATE RECEPTOR; LEVODOPA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOCICEPTIN RECEPTOR; OPIATE RECEPTOR; PHOSPHOPROTEIN DARPP 32; RECEPTOR SUBTYPE;

ARTICLE; BASAL GANGLION; DOPAMINERGIC SYSTEM; DYSKINESIA; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, OPIOID;

EID: 33748683820     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.08.002     Document Type: Article

References (57)

1. Rao G., et al. Does this patient have Parkinson disease?. J. Am. Med. Assoc. 289 (2003) 347-353
2. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
3. Dawson T., et al. Animals models of PD: pieces of the same puzzle?. Neuron 35 (2002) 219-222
4. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
5. Bezard E., et al. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26 (2003) 215-221
6. Mercuri N.B., and Bernardi G. The 'magic' of l-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol. Sci. 26 (2005) 341-344
7. Breit S., et al. Deep brain stimulation. Cell Tissue Res. 318 (2004) 275-288
8. Calon F., et al. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47 (2000) S70-S78
9. Linazasoro G. New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci. 26 (2005) 391-397
10. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13 (1990) 281-285
11. Peckys D., and Landwehrmeyer G.B. Expression of μ, κ, and δ opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88 (1999) 1093-1135
12. 2 receptor agonists. J. Neurochem. 72 (1999) 682-692
13. Quik M., et al. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not l-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 113 (2002) 213-220
14. Meissner W., et al. Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol. Dis. 13 (2003) 46-54
15. Cenci M.A., et al. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
16. Samadi P., et al. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naive parkinsonian monkeys. Neuropharmacology 49 (2005) 165-173
17. Blandini F., et al. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62 (2000) 63-88
18. Vila M., et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: An in situ hybridization study of cytochrome oxidase subunit I mRNA. J. Neurosci. 17 (1997) 765-773
19. Parent A., et al. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 23 (2000) S20-S27
20. Ogura M., and Kita H. Dynorphin exerts both postsynaptic and presynaptic effects in the globus pallidus of the rat. J. Neurophysiol. 83 (2000) 3366-3376
21. Shen K.Z., and Johnson S.W. Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro. J. Physiol. 541 (2002) 219-230
22. Jiang Z.G., and North R.A. Pre- and postsynaptic inhibition by opioids in rat striatum. J. Neurosci. 12 (1992) 356-361
23. Wang H., and Pickel V.M. Preferential cytoplasmic localization of δ-opioid receptors in rat striatal patches: comparison with plasmalemmal μ-opioid receptors. J. Neurosci. 21 (2001) 3242-3250
24. Schneider J.S., et al. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J. Neurosci. 19 (1999) 6643-6649
25. Tel B.C., et al. Alterations in striatal neuropeptide mRNA produced by repeated administration of l-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115 (2002) 1047-1058
26. 2A receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20 (2000) 7782-7789
27. Lindskog M., et al. μ- and δ-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci. 11 (1999) 2182-2186
28. 1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 9 (2003) 455-462
29. Muller D.L., and Unterwald E.M. In vivo regulation of extracellular signal-regulated protein kinase (ERK) and protein kinase B (Akt) phosphorylation by acute and chronic morphine. J. Pharmacol. Exp. Ther. 310 (2004) 774-782
30. Brotchie J.M., et al. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Adv. Neurol. 78 (1998) 41-52
31. Winkler C., et al. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10 (2002) 165-186
32. Westin J.E., et al. Persistent changes in striatal gene expression induced by long term l-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 14 (2001) 1171-1176
33. Calon F., et al. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patient with levodopa-induced dyskinesia. J. Neuropathol. Exp. Neurol. 61 (2002) 186-196
34. Henry B., et al. μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171 (2001) 139-146
35. Samadi P., et al. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 45 (2003) 954-963
36. Samadi P., et al. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol. Dis. 16 (2004) 246-253
37. Abou-Khalil B., et al. Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibers. Brain Res. 323 (1984) 21-29
38. Tokuno H., et al. Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing μ-opioid receptor in rats. Neurosci. Lett. 332 (2002) 5-8
39. Henry B., et al. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 183 (2003) 458-468
40. 1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57 (2005) 17-26
41. Picconi B., et al. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 6 (2003) 501-506
42. Lundblad M., et al. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16 (2004) 110-123
43. Cepeda C., et al. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J. Neurophysiol. 79 (1998) 82-94
44. 1 receptor function by physical interaction with the NMDA receptors. J. Neurosci. 24 (2004) 1149-1158
45. Wang H., et al. μ-opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudate-putamen nucleus. J. Comp. Neurol. 412 (1999) 132-146
46. 2+ channel-regulated neuronal gene expression. J. Neurobiol. 37 (1998) 171-189
47. Williams J.T., et al. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81 (2001) 299-343
48. Greengard P. The neurobiology of slow synaptic transmission. Science 294 (2001) 1024-1030
49. Bédard P.J., et al. Pathophysiology of l-dopa-induced dyskinesias. Mov. Disord. 14 Suppl. 1 (1999) 4-8
50. Chen L., et al. Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys. Neuroscience 132 (2005) 409-420
51. Piccini P., et al. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42 (1997) 720-726
52. 1 receptors in δ opioid receptor-mediated signal transduction. Neuropharmacology 39 (2000) 372-381
53. Nestler E.J. Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol. Sci. 25 (2004) 210-218
54. Waldhoer M., et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9050-9055
55. Samadi P., et al. Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys. Neurobiol. Dis. 19 (2005) 266-272
56. Waldhoer M., et al. Opioid receptors. Annu. Rev. Biochem. 73 (2004) 953-990
57. Norton C.S., et al. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J. Comp. Neurol. 444 (2002) 358-368